Axsome Therapeutics (MIL:1AXSM) Dividends Received


MIL:1AXSM Axsome Therapeutics Inc MIL:1AXSM
30 GF Score
Price €212.90
GF Value €180.51
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

MIL:1AXSM
30GF Score
Axsome Therapeutics Inc MIL:1AXSM
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Axsome Therapeutics (MIL:1AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of €212.90 is trading 17.9% above its estimated GF Value™ of €180.51. GuruFocus considers Axsome Therapeutics to be Modestly Overvalued.

Key valuation signals for MIL:1AXSM:

  • Dividends Received:
  • GF Value™: €180.51 vs. price of €212.90 (17.9% above fair value)
  • GF Score™: 30/100 with 4 warning signs

No single metric tells the full story. See the MIL:1AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Axsome Therapeutics Business Description

Other Exchanges AXSM:USA0HKF:UK19X:Germany
Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
30GF Score

Get the complete analysis for MIL:1AXSM

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€212.90
Price
€180.51
GF Value